News | July 04, 2025
argenx advances clinical development of agonist antibody for myasthenic syndromes
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
The iStent platform uses tiny surgical implants to lower eye pressure by restoring the eye’s natural fluid drainage system in patients with glaucoma
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
Approximately 35% of male cancer patients and 12% of female cancer patients at Paras Health were diagnosed with tobacco-related cancers
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
Phytonadione Injectable Emulsion possesses the same type and degree of activity as does naturally-occurring vitamin K
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
Subscribe To Our Newsletter & Stay Updated
